Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout
Eli Lilly spends more of its GLP-1 cash, Humira’s masterclass in monopoly, and more updates from The Readout
Adobe
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! Hope you had a nice extended weekend.
Today: Eli Lilly’s gene-editing data seems promising for high cholesterol, an AI drug discovery CEO dispelled some AI drug discovery hype, and the new interim FDA chief is so far well received.
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1…
In this week’s edition of InnovationRx, we look at the opportunities and challenges of using AI to personalize healthcare and…
